From Glioblastoma Treatments
Jump to navigationJump to search
Property Information
Drug Name VT-122 (Propranolol and Etodolac combination)
FDA Approval No (VT-122 is an investigational combination of repurposed drugs; Propranolol and Etodolac are FDA-approved for other conditions)
Used for Investigational use in cancer treatment, specifically targeting cachexia in non-small cell lung cancer, hepatocellular carcinoma, and potentially glioblastoma
Clinical Trial Phase Phase 2 (based on ongoing and completed trials for various cancer types)
Clinical Trial Explanation Not specified
Common Side Effects Higher rates of thrombocytopenia, neutropenia, and anemia were observed in some studies
OS without In the glioblastoma study, median overall survival was 9.2 months with low-dose TMZ alone
OS with In the same glioblastoma study, median overall survival was 17.6 months with low-dose TMZ + VT-122
PFS without Not specified
PFS with Not specified; efficacy primarily reported in terms of overall survival and response rates in available studies
Usefulness Rating 4
Usefulness Explanation Not specified
Toxicity Level 3
Toxicity Explanation VT-122 has a toxicity level of 3 out of 5, This means it has moderate toxicity. Some people experiencing the treatment face significant side effects such as thrombocytopenia (low blood platelet count), neutropenia (low count of a type of white blood cell), and anemia (lower than normal level of red blood cells). This could results in increasing fatigue, bruising and bleeding easily, and being more susceptible to infections. However, the severity of these side effects may vary from person to person

Notes: VT-122, combining Propranolol and Etodolac, is under investigation for its potential to enhance survival and reduce cachexia in cancer patients. Preliminary results in glioblastoma suggest a notable improvement in overall survival and response rates when combined with low-dose temozolomide, indicating a promising direction for further research. The study's outcomes, including high response rates and an extended median survival time, highlight VT-122's potential, albeit with the need for more comprehensive trials to fully ascertain its benefits and safety profile.

From Ben Williams Book: Not specified

Loading comments...